← Leaderboards
Adriana H Tremoulet
University Of California, San Diego
$8,401,727
Attributed
$14,381,613
Total exposure
16
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.9M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,221,464 · 19
By mechanism
P50$20,384,978 · 6
R01$5,654,833 · 2
U54$3,538,811 · 3
K12$2,490,811 · 2
T32$1,512,965 · 1
K23$608,850 · 1
Top collaborators
- Victor Nizet18 shared
- Edmund Vincent Capparelli10 shared
- Christina Chambers9 shared
- Lars Bode8 shared
- Shirley M Tsunoda8 shared
- Jane C Burns7 shared
- Harold M Hoffman6 shared
- John Y-J Shyy6 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Victor Nizet$31,303,620
- Shirley M Tsunoda$1,176,383
- Joann Trejo$38,752,283
- Philip Gordts$3,240,157
- Vivian Reznik$6,586,466
Others in their field
Top investigators on “Childhood”
- Gregory H Reaman · National Childhood Cancer Foundation$268,060,146
- Barbara Driver · Westat, Inc.$206,410,885
- Sharon A Nachman · Johns Hopkins University$191,166,598
- Peter C Adamson · National Childhood Cancer Foundation$190,988,407
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$187,267,729
- James E. Gern · University Of Wisconsin-Madison$149,875,125
Research focus
ChildhoodLeadChildPharmacologyProgramsTrainingDrug KineticsResourcesClinical PharmacologyPediatric PharmacologyResearch PersonnelPharmaceutical PreparationsMouse ModelClinical TrialsEnsureMissionBasePublicationsPilot ProjectsInflammatoryLaboratoriesEvaluationResponseImmune Response
Grant awards (64)
CTSA K12 Program at University of California San Diego Altman Clinical and Translational Research Institute$1,612,278
K12 · FY2025 · TR
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,190,453
P50 · FY2025 · HD · contact PI
UC San Diego Raising Advancement and Parity for Infectious Disease Researchers (RAPID) Faculty Development Program$379,080
R25 · FY2025 · AI
National Career Development Program for Researchers in Pediatric Clinical Pharmacology$292,194
K12 · FY2025 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)$196,313
P50 · FY2025 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$189,669
T32 · FY2025 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$3,465,000
P50 · FY2024 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$3,465,000
P50 · FY2024 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,231,207
P50 · FY2024 · HD · contact PI
National Career Development Program for Researchers in Pediatric Clinical Pharmacology$292,194
K12 · FY2024 · HD
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$207,813
T32 · FY2024 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)$196,313
P50 · FY2024 · HD · contact PI
14th Annual International Kawasaki Disease Symposium 2024$7,500
R13 · FY2024 · HL · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,239,102
P50 · FY2023 · HD · contact PI
Diagnosing and predicting risk in children with SARS-CoV-2- related illness$410,937
R33 · FY2023 · HD
National Career Development Program for Researchers in Pediatric Clinical Pharmacology$294,144
K12 · FY2023 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)$196,313
P50 · FY2023 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$170,771
T32 · FY2023 · HD · contact PI
National Career Development Program for Researchers in Pediatric Clinical Pharmacology$1
K12 · FY2023 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$3,069,641
P50 · FY2022 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,250,000
P50 · FY2022 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,015,736
P50 · FY2022 · HD · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$729,091
R01 · FY2022 · HL
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)$192,697
P50 · FY2022 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$153,437
T32 · FY2022 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,250,000
P50 · FY2021 · HD · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$730,641
R01 · FY2021 · HL
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)$196,070
P50 · FY2021 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$155,369
T32 · FY2021 · HD · contact PI
Endothelial Cell and Cardiomyocyte Dysfunction in Children with Kawasaki disease-like SARS-CoV-2 Induced Immune Activation$727,650
R01 · FY2020 · HL
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$716,260
R01 · FY2020 · HL
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$711,940
P50 · FY2020 · HD · contact PI
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$221,408
P50 · FY2020 · HD · contact PI
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki Disease$174,906
P50 · FY2020 · HD · contact PI
Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics$153,075
T32 · FY2020 · HD
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$722,489
P50 · FY2019 · HD · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$710,525
R01 · FY2019 · HL
Refining an Innovative Phase III Trial of Adjunctive Therapy in Acute Kawasaki Disease with Coronary Artery Aneurysms$232,699
U34 · FY2019 · HL
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$223,735
P50 · FY2019 · HD · contact PI
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki Disease$176,655
P50 · FY2019 · HD · contact PI
Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics$142,923
T32 · FY2019 · HD
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$734,233
U54 · FY2018 · HD · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$715,175
R01 · FY2018 · HL
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$223,274
U54 · FY2018 · HD · contact PI
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki Disease$182,752
U54 · FY2018 · HD · contact PI
Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics$139,527
T32 · FY2018 · HD
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$738,651
U54 · FY2017 · HD · contact PI
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease$300,795
R01 · FY2017 · HD · contact PI
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$272,302
U54 · FY2017 · HD · contact PI
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki Disease$177,361
U54 · FY2017 · HD · contact PI
Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics$135,073
T32 · FY2017 · HD
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$756,399
U54 · FY2016 · HD · contact PI
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease$321,906
R01 · FY2016 · HD · contact PI
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$273,769
U54 · FY2016 · HD · contact PI
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki Disease$180,070
U54 · FY2016 · HD · contact PI
Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics$65,308
T32 · FY2016 · HD
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease$61,562
R01 · FY2016 · HD · contact PI
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease$311,856
R01 · FY2015 · HD · contact PI
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease$329,372
R01 · FY2014 · HD · contact PI
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children$121,770
K23 · FY2011 · HD · contact PI
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children$121,770
K23 · FY2010 · HD · contact PI
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children$121,770
K23 · FY2009 · HD · contact PI
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children$121,770
K23 · FY2008 · HD · contact PI
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children$121,770
K23 · FY2007 · HD · contact PI